Volume | 12,778 |
|
|||||
News | - | ||||||
Day High | 0.09 | Low High |
|||||
Day Low | 0.046 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Jasper Therapeutics Inc | JSPRW | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.0699 | 0.046 | 0.09 | 0.09 | 0.0794 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
21 | 12,778 | US$ 0.0740049 | US$ 946 | - | 0.016 - 0.2534 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 100 | US$ 0.09 | USD |
Jasper Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
65.83M | 111.58M | - | 0 | -37.69M | -0.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Jasper Therapeutics News
Real-Time news about Jasper Therapeutics Inc (NASDAQ): 0 recent articles
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JSPRW Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.0455 | 0.09 | 0.0451 | 0.0792801 | 6,841 | 0.0445 | 97.8% |
1 Month | 0.1053 | 0.1082 | 0.0427 | 0.0743022 | 16,372 | -0.0153 | -14.53% |
3 Months | 0.0592 | 0.1499 | 0.04 | 0.0802827 | 23,670 | 0.0308 | 52.03% |
6 Months | 0.078 | 0.1699 | 0.04 | 0.0838917 | 14,487 | 0.012 | 15.38% |
1 Year | 0.049016 | 0.2534 | 0.016 | 0.1219664 | 36,515 | 0.04098 | 83.61% |
3 Years | 1.73 | 2.24 | 0.016 | 0.5939282 | 30,095 | -1.64 | -94.8% |
5 Years | 1.73 | 2.24 | 0.016 | 0.5939282 | 30,095 | -1.64 | -94.8% |
Jasper Therapeutics Description
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. |